%0 Journal Article
%T Collecting Ducts Carcinoma Approach in the New Era of Targeted and Immunotherapy
%A Dany Nassar
%A Nahed Damaj
%A Joseph Kattan
%J Open Journal of Urology
%P 34-44
%@ 2160-5629
%D 2025
%I Scientific Research Publishing
%R 10.4236/oju.2025.152005
%X Collecting duct carcinoma (CDC), or Bellini duct carcinoma, is a rare and aggressive subtype of renal cell carcinoma, accounting for 0.2% - 1% of cases. It often presents at an advanced stage with nonspecific symptoms, requiring histopathology for diagnosis. Surgery remains the standard of care for localized disease, serving both diagnostic and therapeutic purposes, though adjuvant chemotherapy has shown limited efficacy. In metastatic CDC, the gemcitabine-cisplatin regimen is commonly used due to its resemblance to urothelial cancer and supportive data from prospective studies. Newer therapies offer promise in advanced cases. Immune checkpoint inhibitors, such as nivolumab alone or with ipilimumab, have shown benefits in patients with high PD-L1 expression. Targeted therapies like cabozantinib demonstrated efficacy and safety as first-line treatments in phase II trials, while sunitinib and sorafenib have shown responses in various case reports and cohorts. However, combining chemotherapy with bevacizumab did not improve outcomes in phase II trials. Despite therapeutic advances in urothelial cancers and clear cell renal tumors, the CDC entity remains a challenging malignancy, emphasizing the need for continued research to understand the true efficacy of treatment and to prolong survival in advanced disease.
%K Collecting Duct Carcinoma
%K Bellini Tumor
%K Nephrectomy
%K Chemotherapy
%K Targeted Therapy
%K Immunotherapy
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=140844